Dimensional Fund Advisors LP Sells 184,238 Shares of Abbott Laboratories $ABT

Dimensional Fund Advisors LP decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,852,797 shares of the healthcare product maker’s stock after selling 184,238 shares during the period. Dimensional Fund Advisors LP’s holdings in Abbott Laboratories were worth $908,919,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Resolute Wealth Strategies LLC grew its stake in shares of Abbott Laboratories by 21.7% in the 1st quarter. Resolute Wealth Strategies LLC now owns 2,145 shares of the healthcare product maker’s stock worth $220,000 after buying an additional 382 shares during the last quarter. Ironwood Investment Counsel LLC purchased a new position in Abbott Laboratories during the first quarter valued at $1,228,000. Broderick Brian C boosted its holdings in Abbott Laboratories by 4.0% in the first quarter. Broderick Brian C now owns 125,409 shares of the healthcare product maker’s stock worth $12,876,000 after acquiring an additional 4,860 shares in the last quarter. Decker Wealth Management LLC purchased a new stake in shares of Abbott Laboratories in the first quarter worth $1,518,000. Finally, SEB Asset Management AB purchased a new stake in shares of Abbott Laboratories in the first quarter worth $50,522,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Wall Street Analyst Weigh In

ABT has been the topic of several recent analyst reports. BTIG Research increased their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research report on Friday. The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Jefferies Financial Group cut their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Evercore reduced their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $118.61.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Up 0.0%

Shares of Abbott Laboratories stock opened at $100.71 on Monday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company’s 50 day moving average is $89.89 and its 200 day moving average is $102.01. The company has a market cap of $175.41 billion, a price-to-earnings ratio of 32.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.